SCHEMBL23792710

SCHEMBL23792710

CC(C)Cc1sc(NCC(Cc2ccccc2)C(=O)O)nc1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 5/20 0.44
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ KMO O15229 1/20 0.42
▸ POLB P06746 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ FDFT1 P37268 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ PPARG P37231 1/20 0.36
▸ PPARA Q07869 1/20 0.36
▸ DHODH Q02127 1/20 0.36
▸ FPR2 P25090 1/20 0.36
▸ RXRA P19793 1/20 0.36
▸ RXRB P28702 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23792441 0.93 LMNA (0.38) PTGDR2MEN1KMT2AKMOPOLB
SCHEMBL23792699 0.92 PTGDR2 (0.39) PTGDR2MEN1KMT2AKMOPOLB
SCHEMBL23791712 0.92 PTGDR2 (0.43) PTGDR2MEN1KMT2AKMOPOLB
SCHEMBL23792708 0.92 PTGDR2 (0.45) PTGDR2MEN1KMT2AKMOPOLB
SCHEMBL23792442 0.91 CYP3A4 (0.42) PTGDR2MEN1KMT2APOLBNPC1
SCHEMBL23792705 0.91 FDPS (0.40) PTGDR2MEN1KMT2APOLBNPC1
SCHEMBL30173781 0.91 BRAF (0.38) PTGDR2KMOPOLBNPC1LMNA
SCHEMBL23791714 0.91 BRAF (0.38) PTGDR2KMOPOLBNPC1LMNA
SCHEMBL26240315 0.91 NPC1 (0.38) PTGDR2MEN1KMT2AKMOPOLB
SCHEMBL26240327 0.90 FOLH1 (0.41) PTGDR2KMOPOLBNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PTGDR2 4804/4885MEN1 2104/4885KMT2A 1931/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 PTGDR2 4804/4885MEN1 2104/4885KMT2A 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback